dcsimg

This site is intended for healthcare professionals outside of the United States and Canada. If you require specific information relating to your local region, please select country

  • Select your country
    • Germany
    • Spain

Vectibix

Vectibix Website

Vectibix

Vectibix Website

MENU

  • Home
  • About Vectibix®
    • What is Vectibix®
    • How is Vectibix® used in patients with mCRC
    • Vectibix® dosing and administration
    • Vectibix® important safety information
    • Vectibix® dose adjustments
  • Meaningful OS
    • 40 M OS and more
      • PRIME sequencing 40.0 M
      • PRIME wt RAS and LLD 40.7 M
      • PEAK wt RAS/BRAF 41.3 M
      • PEAK Left-sided tumours 43.4 M
      • PLANET wt RAS and LLD
      • PRIME Resected patients 57.4 M
    • Independent of tumour sidedness
      • Left-sided tumours
      • Right-sided tumours
  • More early responders
    • Key studies
      • PRIME
      • PEAK
      • PLANET
    • Improved outcomes
      • Early, deeper, long lasting
      • Improved OS
      • Improved PFS
      • Improved QoL
  • Additional data
    • PRIME
      • Overview
      • Exons examined
      • RAS analysis
      • OS
      • PFS
      • Tumour shrinkage
      • Safety
      • PFS in mutant RAS
      • Summary
    • PEAK
      • Overview
      • Exons examined
      • OS
      • PFS
      • Safety
      • PFS in mutant RAS
      • Summary
    • 20060314 study
      • Overview
      • Exons examined
      • Response rates
      • PFS
      • DoR
      • Safety
      • Summary
    • PLANET study
      • Overview
      • Exons examined
      • ORR + resection
      • PFS
      • OS
      • Safety
      • Summary
    • Additional Studies
      • The 181 study (phase 3 trial)
        • Overview
        • Exon examined
        • OS
        • PFS
        • Safety
        • PFS in mutant RAS
        • Summary
      • The 408 study (phase 3 trial)
        • Overview
        • Exons examined
        • PFS
        • ORR
        • Safety
        • PFS in mutant RAS
        • Summary
  • Hot topics
  • Ask the expert
  • The Vectibix® difference
  • Events

Useful Links and Addresses

Here you will find contact details for important societies and organisations, and links to useful documents.

Cancer societies for healthcare professionals

European Society for Medical Oncology (ESMO)
Via L. Taddei 4
6962 Viganello-Lugano
Switzerland
Tel: +41 (0)91 973 19 00
Fax: +41 (0)91 973 19 02

Web: Click here

American Society of Clinical Oncology (ASCO)
2318 Mill Road
Suite 800
Alexandria, VA 22314
USA
Tel: +1 571 483 1300
Web: Click here

Guidelines

ESMO colorectal cancer guidelines

Schmoll HJ, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalised approach to clinical decision making. Ann Oncol 2012;23:2479-2516.
Web: Click here

Expert Group on OncoSurgery management of Liver Metastases (EGOSLIM) colorectal cancer guidelines on liver metastases

Adam R et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17(10):1225-1239.
Web: Click here


Key Vectibix® references

The PRIME study

Douillard J-Y et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-1034.
Web: Click here

The PEAK study

Schwartzberg L et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014, March 31 (published online before print).
Web: Click here


Other useful links

Management of skin toxicity with anti- EGFR treatment

ESMO: Management of skin toxicities from EGFR inhibitor therapies (for healthcare professionals).
Web: Click here

European Medicines Agency

European Public Assessment Report (EPAR) for Vectibix®
Web: Click here

  • About Vectibix®
  • SPC
  • AE reporting
  • Contact us
  • Links
  • Privacy Policy
  • Terms of Use

This website is not intended for the general public.

Cookies Policy

We use cookies to give you the best experience on our website. If you continue without changing your settings, this will indicate your consent to receive all cookies on the Amgen website. However, if you would like to, you can change your cookie settings at any time. To find out more visit our cookie policy page Terms of Use or Cookie Information for Users

Accept